COMPANY PROFILE

d-Nav

Hygieia commercializes proprietary technology to scale successful diabetes care via its product, Diabetes Insulin Guidance System

Livonia, United StatesFounded 2007Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About d-Nav

Hygieia specializes in providing an innovative Insulin Management Program aimed at optimizing diabetes care for patients. The company serves individuals with diabetes, offering both virtual and in-person consultations primarily through their Livonia clinic. Hygieia operates in the healthcare sector, focusing on diabetes management by providing personalized insulin dosing guidance and regular A1C testing to monitor progress. The business model includes partnerships with insurance providers to cover the cost of the program, and for those without coverage, affordable pricing options are available. Revenue is generated through service fees for the Insulin Management Program, which includes providing testing supplies at no additional cost. The company aims to make diabetes management less intrusive and more effective for patients, ensuring continuous collaboration with their primary care physicians. Keywords: Insulin management, diabetes care, personalized dosing, virtual visits, A1C testing, healthcare, Livonia clinic, insurance partnerships, affordable pricing, patient-centric.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2007
Headquarters: Livonia, United States
Employees: 32
Open positions: None listed
Dealroom signal: 65.3/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Patient Care, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning d-Nav.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	May 2023	$5M	$85M	Firstime	↗
SERIES B✓Equity / VC	Dec 2021	$17M	$68M	Firstime	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

d-Nav website traffic

Latest recorded traffic for d-Nav is 1.1K monthly website visits, down 57.7% over the last three months. d-Nav's team grew 3.2% over the past year.

Latest monthly visits1.1K 3-month web change-57.7% 1-year team growth+3.2%

Monthly website visitsApr 2016–Mar 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GLGlucoSentientPersonal glucose meters for versatile diagnostic monitoring	Champaign, United States	Operational	2	$1.1M	$240K
BTBetalin therapeuticsBetalin's Micro Pancreas is a revolutionary regenerative micro-organ based on cell therapy. It eliminates the need for daily injections, constant blood glucose monitoring, and dietary constraints	Ramat Gan, Israel	Operational
AGAgamatrixAgaMatrix develops and manufactures a line of diabetes products designed to improve the quality of diabetes care	Salem, United States	Operational
MEMedicsenNeedle-free drug delivery platform based on sonophoresis (ultrasounds) to replace needles and cannulas in the transdermal delivery of large molecules	Madrid, Spain	Operational
POPodimetricsDevelops an early warning system to predict and prevent diabetic foot ulcers	Somerville, United States	Operational
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational
NMNeuros MedicalDeveloping proprietary neurostimulation therapies for unmet needs to patients worldwide	Willoughby, United States	Operational
EGEmpire GenomicsLeader in the field of molecular diagnostic services for oncology diseases	Cheektowaga, United States	Acquired